Clinical trial · Interventional
Feasibility of Imaging in the Treatment of Patients With Advanced Head and Neck Cancer
A Pilot Feasibility Study of 99mTc EC DG SPECT/CT Imaging in the Treatment Response Evaluation in Patients With Locally Advanced Head and Neck Cancer
NCT01359267CI-TRIAL-00045003completedEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to obtain preliminary information on the potential of 99m Tc-EC-DG SPECT imaging to distinguish cancer from non cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 99mTc-EC-DG | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Imaging
- interventionNames
- Drug: 99mTc-EC-DG
Primary outcomes (1)
- measure
- Persistent Disease within 6 months of CRT
- timeFrame
- 6 months
Secondary outcomes (1)
- measure
- Persistent Disease within 2 years of CRT
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Treatment naive patients with histologically proven cancer of the head and neck * T4 primary tumor (all sites), N2 or N3 locoregional disease (all sites) * At least one measurable site of disease * At least 18 years of age * Karnofsky performance status \> or = 70% or ECOG \<2 * Able to tolerate SPECT/CT imaging * Adequate bone marrow function * Adequate liver function * Adequate renal function * Written consent from patients * Female patients of childbearing potential must have a negative pregnancy test within 0-7 days prior to the first SPECT study Exclusion Criteria: * Diabetics with insulin dependence or blood sugar levels \>200 mg/dL prior to imaging * Patient weight above the SPECT/CT table weight limit * Pregnant and/or lactating female * Unequivocal demonstration of metastatic disease * Patients unwilling to or unable to comply with protocol
References
Publications (0)
Data not yet available
No reference posted for this study.